Weighing the benefits and downsides of prostate-specific antigen screening.
Publication
, Journal Article
Pignone, M
Published in: Arch Intern Med
September 28, 2009
Duke Scholars
Published In
Arch Intern Med
DOI
EISSN
1538-3679
Publication Date
September 28, 2009
Volume
169
Issue
17
Start / End Page
1554 / 1556
Location
United States
Related Subject Headings
- Risk Assessment
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Practice Guidelines as Topic
- Mass Screening
- Male
- Humans
- General & Internal Medicine
- Age Factors
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Pignone, M. (2009). Weighing the benefits and downsides of prostate-specific antigen screening. Arch Intern Med, 169(17), 1554–1556. https://doi.org/10.1001/archinternmed.2009.269
Pignone, Michael. “Weighing the benefits and downsides of prostate-specific antigen screening.” Arch Intern Med 169, no. 17 (September 28, 2009): 1554–56. https://doi.org/10.1001/archinternmed.2009.269.
Pignone M. Weighing the benefits and downsides of prostate-specific antigen screening. Arch Intern Med. 2009 Sep 28;169(17):1554–6.
Pignone, Michael. “Weighing the benefits and downsides of prostate-specific antigen screening.” Arch Intern Med, vol. 169, no. 17, Sept. 2009, pp. 1554–56. Pubmed, doi:10.1001/archinternmed.2009.269.
Pignone M. Weighing the benefits and downsides of prostate-specific antigen screening. Arch Intern Med. 2009 Sep 28;169(17):1554–1556.
Published In
Arch Intern Med
DOI
EISSN
1538-3679
Publication Date
September 28, 2009
Volume
169
Issue
17
Start / End Page
1554 / 1556
Location
United States
Related Subject Headings
- Risk Assessment
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Practice Guidelines as Topic
- Mass Screening
- Male
- Humans
- General & Internal Medicine
- Age Factors
- 3202 Clinical sciences